Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. (OTC: BLOZF) appears in its public news releases as a developer of marijuana and alcohol breath testing devices for workplaces, law enforcement and other safety-focused environments. The BLOZF news feed on Stock Titan aggregates these disclosures, giving investors and observers a single place to review the company’s reported milestones and product updates.
Company news frequently highlights progress on the Marijuana Breath Test (MBT)
Another recurring topic in Cannabix news is the BreathLogix autonomous alcohol screening platform. Announcements describe sales agreements with customers in sectors such as maritime shipping and oil and gas transportation, integration of BreathLogix with the cloud-based BreathLogix Connect portal, and features such as pre-access alcohol testing, real-time reporting and identity confirmation.
Readers of the BLOZF news page can review updates on regulatory milestones, such as FCC and Canadian emissions testing for the BCU and NHTSA Conforming Products List status for BreathLogix Workplace Series devices, as well as patent developments like the grant of a U.S. patent for contact-free breath analysis. For those tracking Cannabix’s progress in breath-based cannabis and alcohol detection technologies, this news stream offers a consolidated view of the company’s self-reported activities and partnerships over time.
Cannabix Technologies (OTCID: BLOZF) announced commercial delivery of its Marijuana Breath Test (MBT) to a Virginia industrial manufacturing client on April 1, 2026, completed via an authorized reseller.
The MBT detects delta-9 THC in breath within four hours above 5 pg/L, uses proprietary Breath Collection Unit and laboratory LC-MS analysis, and leverages a strategic partnership with Omega Laboratories.
Cannabix Technologies (OTCID: BLOZF) announced the first commercial delivery of its Marijuana Breath Test (MBT) to a major construction contractor on March 19, 2026. The MBT detects delta-9 THC in breath within approximately four hours at levels above 5 pg/L and uses single-use Breath Cartridges plus a Breath Collection Unit.
The company partners with Omega Laboratories for LC-MS laboratory analysis and plans to scale production through resellers targeting safety-sensitive sectors such as construction, transportation, and manufacturing.
Cannabix Technologies (OTCID: BLOZF) has commenced a phased commercial rollout of its Marijuana Breath Test (MBT) system, delivering units to select customers starting March 16, 2026. The MBT detects recent delta-9 THC in breath at >5 pg/L within ~4 hours of use and follows a recurring revenue model using disposable cartridges.
Key rollout enablers include a peer-reviewed Journal of Analytical Toxicology publication, partnership with Omega Laboratories for lab methods and LIMS integration, FCC emissions approval for the Breath Collection Unit, and established manufacturing, QA/QC, and training materials.
Omega Laboratories and Cannabix Technologies (OTCID: BLOZF) announced a peer‑reviewed validation published March 3, 2026 in the Journal of Analytical Toxicology confirming an LC‑MS/MS laboratory method to detect multiple cannabinoids in breath collected with the Cannabix Breath Collection Unit.
The study reports simultaneous quantification of Δ9‑THC, Δ8‑THC, CBD, and CBN, breath sample stability up to 7 days, and a detection window correlating with blood for recent use (about 15 minutes to 4 hours).
Cannabix Technologies (OTCID: BLOZF) announced its Marijuana Breath Test (MBT) will appear on the cover of AlcoPro 2026 product catalogue, which will be distributed to more than 85,000 businesses in the U.S. and internationally, including law enforcement and corrections.
Cannabix and AlcoPro are collaborating on pre-launch U.S. marketing for the MBT. The MBT combines Cannabix’s Breath Collection Unit and Breath Cartridge for non-invasive breath sampling intended for LC-MS analysis. Cannabix also highlights a strategic partnership with Omega Laboratories, a forensic drug-testing provider with over 25 years of certifications and experience.
Cannabix Technologies (OTCID: BLOZF) launched new product videos on Dec. 19, 2025 showcasing its Marijuana Breath Test (MBT) and related hardware, including the Breath Collection Unit (BCU) and Breath Cartridge (BC).
The videos describe the MBT’s non-invasive breath sampling to detect recent cannabis use and show integration with gold-standard LC-MS analysis and a strategic partnership with Omega Laboratories for commercialization in the U.S. and Canada.
The company links the MBT to growing demand following the U.S. Administration’s reclassification action and positions the device for workplace and roadside screening applications.
Cannabix Technologies (OTCID: BLOZF) announced that its handheld Breath Collection Unit (BCU) passed electronic emissions testing required by the US Federal Communications Commission (FCC) and Canada’s ISED standard ICES-003 Issue 7. Cannabix received an ISO/IEC 17025 accredited test report after testing at QAI Laboratories in British Columbia. The BCU and proprietary Breath Cartridges form the core of the Marijuana Breath Test (MBT) system, which aims to collect stable breath samples for analysis by LC-MS. Cannabix said this emissions clearance is a key regulatory milestone toward commercialization in the US and Canada.
Cannabix Technologies (OTCID: BLOZF) announced a second sales agreement to deliver an additional BreathLogix unmanned alcohol screening unit to an existing European maritime customer on Dec 2, 2025.
The device will integrate with the cloud-based BreathLogix Connect platform (powered by Amazon Web Services) for real-time alerts, centralized data management and reporting, and will include facial recognition for crew identification. BreathLogix supports multiple workplace testing scenarios and is listed on the U.S. Federal Register Conforming Products List (NHTSA). The system uses a patent-pending pre-calibrated sensor cartridge to reduce maintenance needs.
Cannabix Technologies (OTC: BLOZF) announced that the United States Patent and Trademark Office granted patent No. 18/1729,658 on Oct 27, 2025 for a “Contact-Free Breath Analysis Device and Method.”
The patent covers Cannabix's dual‑mode contactless and mouthpiece breath capture and analysis used in its BreathLogix platform, enabling unmanned devices, real‑time visual feedback, adaptive airflow control, and compact modular designs for vehicles, workplaces, public kiosks, law enforcement, workplace safety, and public health monitoring.
Cannabix Technologies (OTC: BLOZF) announced delivery of its BreathLogix alcohol screening device to an oil and gas transportation services company in northern Alberta on October 16, 2025.
The unmanned system records BrAC/BAC, captures a user photo, logs results on a BreathLogix Connect web portal, sends real-time alerts by SMS and e-mail, and supports integration with access control and fleet systems. The Workplace Series has been added to the NHTSA Conforming Products List (CPL) for breath alcohol screen devices.
On October 15, 2025, the company signed a three-month marketing services agreement with Black Swan Solutions dba VHLA Media for C$100,000 plus GST; no securities will be issued as payment.